Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today that management will present at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 8:45 a.m. ET.

A link to the live and archived webcast may be accessed on Opus Genetics’ website under the Investors section: Events.

About Opus Genetics

Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RDH12, MERTK, RHO, CNGB1 and NMNAT1. The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com.

Contacts:

Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
[email protected]

Media
Kimberly Ha
KKH Advisors
917-291-5744
[email protected]

Source: Opus Genetics, Inc.

You May Also Be Interested In

• New Crypto Pepeto Announces Crossing 41,000 Buyers Fast as the BNB Price Prediction Targets $1,755
• TD Cowen on Opus Genetics (IRD): 'High Conviction For Meaningful Efficacy'
• Elseland Showcases New Possibilities for AI Game Creation with 20 Original Titles